AHK-Cu vs GHK-Cu: One Amino Acid, Two Research Stories

In 1973, a biochemist named Loren Pickart was trying to figure out why liver cells taken from older patients died off in culture while liver cells from younger donors kept dividing. On a hunch, he swapped the culture medium — bathing the old cells in young plasma instead. The old cells perked up. Something in young blood was keeping tissue alive and telling it to repair itself, and when Pickart went looking for the active ingredient, he didn’t find a hormone or a growth factor. He found a fragment three amino acids long, bound to a single copper ion, hiding in plain sight in ordinary human plasma.

That tripeptide — glycyl-L-histidyl-L-lysine, or GHK — turned out to be one of the more consequential small molecules in peptide research history. Complexed with copper, as GHK-Cu, it has spent five decades accumulating a research trail that spans wound repair, collagen biology, antioxidant gene expression and tissue remodeling. More recently, a close structural cousin has entered the picture: AHK-Cu, in which the glycine at position one is swapped for alanine. Same copper-binding backbone, one different residue, and a research story that’s really just getting started.

This article lines the two compounds up side by side — where they came from, what actually differs between them at the molecular level, what the published research says about each, and why the manufacturing behind a copper-peptide complex matters as much as the peptide sequence itself.

Crown Peptides supplies AHK-Cu, GHK-Cu and other copper-binding peptides for laboratory and research use only — these compounds are not intended for human consumption and are not approved as drugs, medicines or cosmetic treatments.

• GHK-Cu occurs naturally in human plasma and was first isolated and characterized by Loren Pickart in 1973, making it one of the longest-studied signalling peptides in the research literature.
• AHK-Cu differs from GHK-Cu by a single N-terminal residue — alanine in place of glycine — while sharing the identical His-Lys-Cu coordination chemistry that does most of the copper-binding work.
• GHK-Cu’s published research base spans collagen synthesis, fibroblast and keratinocyte proliferation, antioxidant and anti-inflammatory gene expression, and tissue-remodeling mechanisms studied across multiple decades.
• AHK-Cu’s research base is smaller and newer, anchored by a targeted study on dermal papilla cell proliferation and ex vivo hair-follicle elongation — a distinct, named analog rather than an untested variant.
• Both compounds are supplied by Crown Peptides as high-purity lyophilized research material, with every batch independently verified by HPLC and mass spectrometry before dispatch.

The Plasma Discovery Nobody Was Looking For

Pickart wasn’t setting out to discover a peptide. He was a biochemist puzzling over cell senescence, and the liver-culture experiment was really a side investigation into why aged tissue loses its regenerative capacity. The result surprised him enough that he chased it down to a molecular level, and in 1973 he and co-author Michael Thaler published the finding in Nature New Biology: a tripeptide isolated from human serum that prolonged the survival of normal liver cells in culture and stimulated growth specifically in neoplastic liver tissue.¹ A companion paper the same year, published with Larry Thayer in Biochemical and Biophysical Research Communications, confirmed the synthetic version of the tripeptide reproduced the effect. The sequence was glycyl-L-histidyl-L-lysine — three amino acids, unremarkable on paper, except for one property that made it biologically interesting: an unusually high binding affinity for copper(II) ions, on the same order as the copper-transport site on human serum albumin itself.

That affinity turned out to be the whole story. Copper is essential to dozens of enzymatic processes involved in tissue repair — lysyl oxidase, which cross-links collagen and elastin, is copper-dependent, and so are several antioxidant enzyme systems. But free copper ions are also reactive and potentially damaging if they’re not chaperoned properly. GHK appears to function as a natural copper courier: it binds circulating copper, forms the GHK-Cu complex, and appears able to move that copper to where tissue-remodeling processes need it, while the peptide’s own biochemistry also triggers a signalling cascade that recruits repair cells to the site.

This is part of why GHK-Cu is often described as a copper chaperone rather than simply a “copper-binding peptide.” The distinction matters biochemically: a chaperone doesn’t just sequester a metal ion, it moves it somewhere specific and hands it off under controlled conditions. Serum albumin is the body’s main copper-transport protein in circulation, and GHK’s copper affinity sits in a similar range to albumin’s own N-terminal copper-binding site — close enough that researchers have proposed GHK can compete for, and take up, copper already bound to albumin, effectively redirecting it toward tissue that needs it for repair-related enzymatic processes. That’s a more targeted role than passive metal-binding, and it’s consistent with the pattern researchers keep finding: GHK-Cu’s effects cluster tightly around processes that are directly copper-dependent, rather than showing up as generic, non-specific biological activity.

What makes this more than a laboratory curiosity is that GHK-Cu isn’t a synthetic invention grafted onto human biology from outside — it’s already there. It circulates naturally in human blood plasma, and its concentration isn’t static across a lifespan. A 2020 review from researchers at the University of Washington’s Department of Comparative Medicine reported that plasma GHK levels average around 200 ng/mL at age twenty and decline to roughly 80 ng/mL by age sixty — a more than twofold drop that tracks the same general timeline as the visible decline in tissue repair capacity and skin elasticity that comes with aging.⁴ That correlation is exactly what got researchers interested in GHK-Cu as a subject worth sustained study in the first place, and it’s a large part of why the compound has accumulated such a long publication history: a molecule that’s naturally abundant in young, actively-repairing tissue and measurably scarcer in older tissue is an obvious candidate for mechanistic research into what tissue remodeling actually requires at a molecular level.

One Residue Apart: What Actually Changes Between the Two

Here’s where the comparison gets genuinely interesting from a chemistry standpoint, because AHK-Cu isn’t a rough approximation of GHK-Cu — it’s a deliberately close structural analog, and the specific way it’s close matters.

Both peptides share an identical histidine-lysine backbone in positions two and three. That’s not a coincidence; it’s the part of the molecule doing most of the copper-coordination work. Copper(II) in these tripeptide complexes is typically held in a roughly square-planar arrangement, coordinated by the free N-terminal amino group, two deprotonated backbone amide nitrogens, and the imidazole nitrogen of the histidine side chain. Histidine and lysine are essentially non-negotiable for that geometry — swap either one out and you’d fundamentally change how (or whether) the complex forms at all.

The N-terminal residue is a different story. Glycine, at that position in GHK-Cu, is the simplest possible amino acid — its side chain is a single hydrogen atom, contributing essentially no steric bulk and no meaningful hydrophobicity. Alanine, in AHK-Cu, adds a methyl group in that same position. It’s a small change on paper: one extra carbon, three extra hydrogens, molecular weight up by about 14 daltons once you account for the copper complex overall. But that methyl group sits right next to the copper-binding amine, and in peptide chemistry, small substitutions adjacent to a metal-binding site can meaningfully shift the complex’s electronic environment, its solution stability, and how the molecule interacts with cell-surface receptors and transporters — without disrupting the core coordination chemistry that makes it a copper-binding tripeptide in the first place.

There’s also a practical, physical-chemistry dimension to the substitution worth noting. Adding a methyl group nudges the molecule’s overall hydrophobicity slightly upward compared to the unsubstituted glycine backbone. In peptide chemistry, even small shifts in hydrophobicity can influence how readily a molecule partitions across lipid membranes, how it behaves during formulation and storage, and how it interacts with transport proteins in solution. None of that changes the fundamental identity of the compound as a copper-chelating tripeptide — the coordination chemistry is the same family of chemistry either way — but it’s exactly the kind of variable that structure-activity research is designed to isolate and measure rather than assume.

That’s the underlying logic behind comparing the two compounds at all. Researchers working with structure-activity relationships often build a close analog specifically to isolate which biological effects come from the shared backbone and which come from the variable residue. If AHK-Cu and GHK-Cu behave identically in a given assay, that points toward the His-Lys-Cu core as the active driver. If they diverge, the alanine substitution is doing something specific — and that’s exactly the kind of open question the current AHK-Cu literature is chipping away at, one study at a time.

Fifty Years of Data Behind One Small Molecule

GHK-Cu’s research base didn’t happen all at once. It built up in layers, starting with cell-culture mechanism work and eventually broadening into gene-expression profiling, and it’s worth walking through a few of the specific, named studies rather than treating “GHK-Cu is well researched” as an unsupported blanket claim.

The clearest early example came in 1988, when Francois-Xavier Maquart and colleagues — working with Pickart himself as a co-author — published a study in FEBS Letters examining GHK-Cu’s effect on collagen synthesis in cultured human skin fibroblasts.² They found a stimulating effect on collagen production that began at concentrations as low as 10⁻¹² M, maximized around 10⁻⁹ M, and — notably — occurred independently of any change in overall cell number, meaning the peptide was driving existing fibroblasts to produce more collagen rather than simply increasing how many cells were present. The paper included a detail that’s stuck in the literature ever since: the GHK sequence itself appears as a triplet within the alpha-2 chain of type I collagen. The implication is elegant — proteases breaking down damaged collagen at a wound site may liberate free GHK as a byproduct, which then binds available copper and signals the surrounding tissue to begin rebuilding. Damage and repair, encoded in the same molecule.

Two decades later, Pickart published a comprehensive review in the Journal of Biomaterials Science, Polymer Edition that catalogued the breadth of remodeling-related actions attributed to GHK and GHK-Cu across the accumulated literature by that point.³ The review described four broad categories of activity: chemoattraction of repair cells including macrophages, mast cells and capillary cells to a site of injury; anti-inflammatory actions, including suppression of free radicals, thromboxane formation and pro-inflammatory signalling molecules like TNF-alpha, alongside increases in protective antioxidant enzyme activity such as superoxide dismutase; increased synthesis of structural and signalling proteins including collagen, elastin, several growth factors and metalloproteinases involved in tissue turnover; and increased proliferation of fibroblasts and keratinocytes, alongside effects on nerve outgrowth, angiogenesis and hair follicle size observed across various experimental models. That’s a genuinely wide mechanistic footprint for a three-amino-acid molecule, and it’s the reason GHK-Cu shows up across such a range of research contexts — dermatology, wound biology, and increasingly, aging research.

Wound-healing research has also extended into whole-animal models rather than stopping at cell culture. A 2003 study published in Veterinary Surgery by Canapp and colleagues at the University of Florida tested a topical glycyl-L-histidyl-L-lysine tripeptide-copper complex on ischemic open wounds in rats, using a controlled bipedicle skin-flap model designed to mimic the poor blood supply seen in chronic, slow-healing wounds.⁶ Over thirteen days, treated wounds closed significantly faster than untreated controls — 64.5% reduction in wound area versus 28.2% in the control group — and biopsied tissue from the treated wounds showed significantly lower concentrations of TNF-alpha and the tissue-remodeling enzymes MMP-2 and MMP-9, both markers of a wound environment that’s less inflamed and further along in the repair process. It’s an animal model rather than a human clinical trial, and the authors themselves noted that clinical evaluation was still warranted — but it’s a controlled, quantitative demonstration of exactly the mechanism the fibroblast and gene-expression research would predict.

It’s also worth mentioning, plainly and without overstating it, that GHK-Cu has a life outside the research lab: it’s a recognized cosmetic ingredient, listed under the INCI name Copper Tripeptide-1, and appears in commercial skincare formulations sold at consumer cosmetic concentrations. That’s simply a fact about the molecule’s broader profile and how the cosmetics industry has used it — it doesn’t describe what Crown Peptides’ research-grade material is intended or sold for, which is laboratory and research use in its lyophilized, analytical-grade form.

You can explore Crown Peptides’ full GHK-Cu research peptide listing directly, and there’s a deeper dive into the compound’s chemistry and research background in the GHK-Cu peptide guide.

The Newer Analog Building Its Own Research Base

AHK-Cu doesn’t have fifty years behind it, and there’s no reason to pretend otherwise — but “newer” and “smaller” aren’t the same as “untested.” One of the clearest, most specific pieces of published research on AHK-Cu came out of Seoul National University’s Department of Dermatology in 2007, when Pyo and colleagues set out to test the tripeptide-copper complex’s effect on human hair growth directly.⁵

The study is worth describing in some detail because it’s a genuinely targeted piece of work, not a passing mention. The researchers used the compound explicitly identified as L-alanyl-L-histidyl-L-lysine-Cu²⁺ — AHK-Cu by name — and tested it on two systems: intact human hair follicles maintained ex vivo, and cultured dermal papilla cells (DPCs), the specialized fibroblast-like cells that regulate hair follicle growth cycles. At concentrations between 10⁻¹² and 10⁻⁹ M, AHK-Cu stimulated measurable elongation of the hair follicles and increased proliferation of the cultured DPCs. Looking for a mechanism, the team ran flow cytometry on the DPCs and found that AHK-Cu treatment shifted the balance of apoptosis-related proteins: the Bcl-2/Bax ratio increased, and the cleaved, active forms of caspase-3 and PARP — both markers of a cell actively undergoing programmed death — were reduced. The proposed interpretation was that AHK-Cu promotes follicle growth partly through direct proliferation of dermal papilla cells and partly by making those cells less prone to apoptosis under the tested conditions.

That’s a real, named, mechanistically-specific ex vivo and in vitro study — not a vague gesture at “some research exists.” It’s also, honestly, a fairly natural thing to have investigated: researchers already familiar with GHK-Cu’s known effect on hair follicle size in broader tissue-remodeling studies had an obvious reason to test whether a close structural analog reproduced or altered that specific effect, and the dermal papilla cell system gave them a clean, well-established assay to run it in.

Beyond that anchor study, AHK-Cu shows up increasingly often in peptide-research circles as a compound of interest precisely because of its structural proximity to GHK-Cu — researchers comparing the two are effectively running a natural structure-activity experiment, one amino acid at a time. It’s also true that anecdotal reports occasionally circulate among peptide researchers noting apparent differences in solution behavior or handling characteristics between AHK-Cu and GHK-Cu preparations; that’s worth mentioning as a real pattern people talk about, but it’s anecdotal, not data, and shouldn’t be treated as established fact until it’s actually been characterized in a published study. These informal reports are not research data, and Crown Peptides does not condone personal or human use of research compounds.

The honest framing is this: GHK-Cu is the deeply characterized reference compound in this pairing, and AHK-Cu is the newer analog whose research base is still being written — which, for anyone doing comparative or structure-activity work, is exactly what makes it interesting to have on hand. You can find Crown Peptides’ AHK-Cu research peptide listed at 100mg, and the AHK-Cu peptide guide goes further into its structure and analytical profile.

Why Purity Isn’t a Detail You Skip With Copper Complexes

Copper-binding tripeptides are a genuinely different manufacturing challenge than a standard linear peptide chain, and it’s worth explaining why, because it’s the reason batch-level verification matters more here than it might for some other compound classes.

With a peptide like GHK or AHK on its own, purity testing is mostly about confirming the amino acid sequence assembled correctly and that residual synthesis byproducts were removed. Once copper enters the picture, there’s a second variable: whether the copper is actually chelated into the intended tripeptide-copper complex, in the correct coordination geometry, rather than present as free copper ions loosely associated with unchelated peptide, or as a partially oxidized or degraded copper species. A sample that “looks right” by a crude visual check — GHK-Cu and AHK-Cu solutions both carry a characteristic blue-violet color typical of copper(II) complexes — can still contain a meaningful fraction of material that isn’t properly complexed, and that distinction genuinely matters for anyone running a controlled experiment, because free copper ions and a stable tripeptide-copper chelate are not chemically interchangeable.

Short-chain peptides like these add a further analytical wrinkle: at only three amino acids plus a chelated metal center, there’s proportionally less molecular “signature” to work with than in a longer peptide chain, which means low-quality synthesis byproducts or incompletely chelated material can be harder to distinguish from the target compound without genuinely rigorous analytical methods, not just a basic assay. That’s precisely why Crown Peptides tests every batch of both compounds using high-performance liquid chromatography (HPLC) to verify purity, and mass spectrometry to confirm molecular identity — not just that a peptide of roughly the right mass is present, but that the mass matches the expected copper complex specifically. Each batch is issued its own certificate of analysis rather than relying on a single reference test applied across an entire production run, which matters because synthesis and chelation efficiency can vary batch to batch even under controlled conditions. Both AHK-Cu and GHK-Cu are supplied at a verified purity of 99% or higher.

Storage and handling matter for the same underlying reason. Lyophilized (freeze-dried) copper-peptide powder is comparatively stable when kept sealed, protected from light and moisture, and stored at -20°C, but copper(II) complexes are redox-active by nature — once reconstituted into solution, they’re more susceptible to oxidative degradation over time, particularly with repeated freeze-thaw cycling or extended exposure to ambient light and air. The practical research guidance is straightforward: keep the lyophilized powder in proper cold storage until use, reconstitute only the volume needed for a given experiment, and avoid unnecessary freeze-thaw cycles on prepared solutions. It’s a small set of handling habits, but for a compound class where the metal-binding state is central to what’s actually being studied, it’s the difference between working with well-characterized material and introducing an uncontrolled variable into your own data.

Frequently Asked Questions

Is the wound-healing research behind GHK-Cu based on human trials?

The published research spans several model types rather than one single study design — cultured human fibroblasts in the Maquart 1988 work, ischemic wounds in rats in the Canapp 2003 study, and broader mechanistic review work summarizing effects observed across models. That’s a genuinely broad evidence base for a research compound, but it’s accurate to describe it as preclinical and cell-based research rather than completed large-scale human clinical trials.

Is AHK-Cu just GHK-Cu with a small tweak, or a genuinely different compound?

It’s a distinct, separately registered compound — AHK-Cu carries its own CAS number (767286-83-9), its own molecular formula and weight, and its own dedicated research, including the Pyo et al. dermal papilla cell and hair-follicle study described above. The relationship is best described as a close structural analog built on a shared copper-binding backbone, not a modified or “upgraded” version of GHK-Cu.

Does GHK-Cu’s larger research base mean it’s more potent than AHK-Cu?

Not necessarily, and it’s an easy assumption to make incorrectly. A larger publication history means a compound has been characterized across more assay types and experimental models — it doesn’t by itself establish that the compound produces a stronger biological effect than a less-studied analog. Direct head-to-head potency comparisons between AHK-Cu and GHK-Cu in matched assay conditions are limited, which is itself part of why the two are an interesting pair for comparative research.

Why do GHK-Cu and AHK-Cu solutions have that distinctive blue-violet color?

It’s a characteristic feature of copper(II) coordination complexes generally — the color comes from d-d electronic transitions within the copper ion once it’s bound in the square-planar arrangement formed with the tripeptide. It’s a useful visual indicator that a copper complex is present, but it isn’t a substitute for actual analytical verification, since color alone can’t confirm complex purity or concentration.

What’s the difference between the CAS number for GHK and the CAS number for GHK-Cu?

They’re registered as separate substances because they’re chemically different entities. The free tripeptide glycyl-L-histidyl-L-lysine (without copper) carries CAS 49557-75-7, while the copper(II)-chelated complex — GHK-Cu, the form referenced throughout this article and the one Crown Peptides supplies — is separately registered under CAS 89030-95-5. The same logic applies across copper-peptide chemistry generally: the ligand and the metal complex are distinct registered substances, even when people use the names loosely in conversation.

How should lyophilized copper peptides be stored between uses?

Keep the lyophilized powder sealed, protected from light and moisture, and stored at -20°C until it’s needed. Once reconstituted, use the solution promptly and avoid repeated freeze-thaw cycling, since the copper coordination in these complexes is more vulnerable to oxidative degradation in solution than in the dry, freeze-dried state.

Two Compounds, One Backbone, and a Research Story Still Being Written

Line them up and the relationship between these two peptides looks almost like a controlled experiment nature handed researchers for free: identical copper-binding chemistry, one variable residue, and fifty years of accumulated data on one side against a compact but genuinely promising body of targeted research on the other. That’s not a weakness in the comparison — it’s what makes AHK-Cu worth watching. Every well-characterized reference compound started somewhere, and the studies coming out on AHK-Cu right now, from dermal papilla cell proliferation to hair-follicle elongation ex vivo, are exactly the kind of foundational, mechanism-focused work that GHK-Cu’s own research history was built from in its earlier years.

For researchers running comparative work, structure-activity studies, or simply looking to work with high-purity copper-binding tripeptides backed by verifiable analytical data, both compounds are available now. Crown Peptides supplies AHK-Cu and GHK-Cu as lyophilized research-grade material, each batch independently verified by HPLC and mass spectrometry with its own certificate of analysis. Browse the full research peptide range at the Crown Peptides homepage, or head straight to the product pages to see current batch documentation for either compound.